Interações de Ondansetrona

Ondansetrona (Zofran, Zuplenz), medicamento que prolonga o intervalo QT, tem 201 interações documentadas nas bulas da FDA e nas fichas informativas que indexamos (graves: 111; moderadas: 62; leves: 25; casos em que uma bula relata não haver interação significativa: 3). Cada item abaixo cita a frase em que se baseia. Esta página de medicamento é um ponto de partida, não um veredito para a sua situação.

Interações segundo a bula

Interações graves (111)

  • AlmotriptanatriptanoGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • AmiodaronaantiarrítmicoGrave

    Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent. (bula de Amiodarona, Advertências e precauções)

  • Amitriptilinaantidepressivo tricíclicoGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Amoxapinaantidepressivo tricíclicoGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Anfetaminaestimulante do SNCGrave

    Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (bula de Anfetamina, Advertências e precauções)

  • Anfetamina + dextroanfetaminaestimulante do SNCGrave

    Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (bula de Anfetamina + dextroanfetamina, Advertências e precauções)

  • Azitromicinaantibiótico macrolídeoGrave

    This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (bula de Azitromicina, Advertências e precauções)

  • Azul de metilenoinibidor da MAOGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Beladona + ópioopioideGrave

    • Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Beladona + ópio, Interações medicamentosas)

  • Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • BuprenorfinaopioideGrave

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Buprenorfina, Interações medicamentosas)

  • Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Buprenorfina + naloxona, Interações medicamentosas)

  • Buspironamedicamento serotoninérgicoGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Butalbital + ácido acetilsalicílico + cafeína + codeína, Interações medicamentosas)

  • • Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Butalbital + paracetamol + cafeína + codeína, Interações medicamentosas)

  • ButorfanolopioideGrave

    …medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Butorfanol, Precauções)

  • Ciclobenzaprinarelaxante muscularGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • CiprofloxacinofluoroquinolonaGrave

    Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval. (bula de Ciprofloxacino, Advertências e precauções)

  • CitalopramISRSGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Clomipraminaantidepressivo tricíclicoGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • CodeínaopioideGrave

    • Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Codeína, Interações medicamentosas)

  • Desipraminaantidepressivo tricíclicoGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Dextroanfetaminaestimulante do SNCGrave

    Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans,… (bula de Dextroanfetamina, Advertências)

  • Dextrometorfanomedicamento serotoninérgicoGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Dextrometorfano + quinidinamedicamento serotoninérgicoGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Di-hidroergotaminaalcaloide do ergotGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • DofetilidaantiarrítmicoGrave

    Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. (bula de Dofetilida, Advertências)

  • Doxepinaantidepressivo tricíclicoGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • DuloxetinaIRSNGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • EletriptanatriptanoGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (bula de Entricitabina + rilpivirina + tenofovir, Advertências e precauções)

  • Erva-de-são-joão (hipérico)Fitoterápicos e suplementosGrave

    Combinar a erva-de-são-joão (hipérico) com antidepressivos e outros medicamentos serotoninérgicos aumenta o risco de síndrome serotoninérgica. (NCCIH, St. John's Wort)

  • EscitalopramISRSGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Fenelzinainibidor da MAOGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • FenobarbitalbarbitúricoGrave

    Drugs that Prolong the QT Interval : Avoid concomitant use. (bula de Fenobarbital, Interações medicamentosas)

  • FentanilaopioideGrave

    • Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (bula de Fentanila, Advertências e precauções)

  • Flibanserinadepressor do SNCGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Fluconazolantifúngico azólicoGrave

    Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (bula de Fluconazol, Contraindicações)

  • FluoxetinaISRSGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • FluvoxaminaISRSGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • FoscarneteantiviralGrave

    (See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (bula de Foscarnete, Interações medicamentosas)

  • FosfomicinaantibióticoGrave

    Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (bula de Fosfomicina, Interações medicamentosas)

  • FrovatriptanatriptanoGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Granisetronamedicamento que prolonga o intervalo QTGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • HidrocodonaopioideGrave

    Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Hidrocodona, Interações medicamentosas)

  • Serotonergic drugs : Concomitant use may result in serotonin syndrome. (bula de Hidrocodona + clorfeniramina, Interações medicamentosas)

  • Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Hidrocodona + homatropina, Interações medicamentosas)

  • S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Hidrocodona + ibuprofeno, Precauções)

  • Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Hidrocodona + paracetamol, Precauções)

  • HidromorfonaopioideGrave

    • Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Hidromorfona, Interações medicamentosas)

  • Hidroxicloroquinamedicamento que prolonga o intervalo QTGrave

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (bula de Hidroxicloroquina, Advertências e precauções)

  • IloperidonaantipsicóticoGrave

    Avoid the use of FANAPT in combination with any other drugs that prolong the QT interval [see Warnings and Precautions (5.3) ] . (bula de Iloperidona, Interações medicamentosas)

  • Imipraminaantidepressivo tricíclicoGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (bula de Ivabradina, Advertências e precauções)

  • LevofloxacinofluoroquinolonaGrave

    Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval ( 5.11 , 8.5 ) (bula de Levofloxacino, Advertências e precauções)

  • S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • LevorfanolopioideGrave

    Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Levorfanol, Precauções)

  • LinezolidaantibióticoGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Lisdexanfetaminaestimulante do SNCGrave

    Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (bula de Lisdexanfetamina, Advertências e precauções)

  • Lítiomedicamento serotoninérgicoGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Lopinavir + ritonavirantirretroviralGrave

    Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval. (bula de Lopinavir + ritonavir, Advertências e precauções)

  • MetadonaopioideGrave

    Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (bula de Metadona, Advertências e precauções)

  • Metanfetaminaestimulante do SNCGrave

    Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (bula de Metanfetamina, Advertências e precauções)

  • Metaxalonarelaxante muscularGrave

    Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (bula de Metaxalona, Interações medicamentosas)

  • MilnacipranaIRSNGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • MirtazapinaantidepressivoGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • MorfinaopioideGrave

    • Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Morfina, Interações medicamentosas)

  • NaratriptanatriptanoGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • NefazodonaantidepressivoGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Nortriptilinaantidepressivo tricíclicoGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Olanzapina + fluoxetinaantipsicóticoGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • OliceridinaopioideGrave

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Oliceridina, Interações medicamentosas)

  • Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (bula de Oxaliplatina, Interações medicamentosas)

  • OxicodonaopioideGrave

    Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (bula de Oxicodona, Interações medicamentosas)

  • OximorfonaopioideGrave

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Oximorfona, Interações medicamentosas)

  • Palonosetronamedicamento serotoninérgicoGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Paracetamol + codeína, Precauções)

  • ParoxetinaISRSGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (bula de Pazopanibe, Interações medicamentosas)

  • Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Pentazocina + naloxona, Precauções)

  • Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • PimozidaantipsicóticoGrave

    Because pimozide prolongs the QT interval of the electrocardiogram it is contraindicated in patients with congenital long QT syndrome, patients with a history of cardiac arrhythmias, patients taking other drugs which prolong the QT interval of the electrocardiogram or patients with known hypokalemia or hypomagnesemia (see also PRECAUTIONS - DRUG INTERACTIONS ). (bula de Pimozida, Contraindicações)

  • Pitolisantomedicamento que prolonga o intervalo QTGrave

    The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

  • Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Prometazina + codeína, Interações medicamentosas)

  • Prometazina + dextrometorfanoanti-histamínicoGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • PropafenonaantiarrítmicoGrave

    • Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (bula de Propafenona, Advertências e precauções)

  • Protriptilinaantidepressivo tricíclicoGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Prucalopridamedicamento serotoninérgicoGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Rasagilinainibidor da MAOGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • RemifentanilaopioideGrave

    • Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (bula de Remifentanila, Advertências e precauções)

  • RizatriptanatriptanoGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Selegilinainibidor da MAOGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • SertralinaISRSGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Solriamfetolestimulante do SNCGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • SumatriptanatriptanoGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • TapentadolopioideGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Tetrabenazinainibidor do VMAT2Grave

    Certain conditions may increase the risk for torsade de pointes or sudden death such as (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval [see Warnings and Precautions ( 5.8 ), Clinical Pharmacology (12.2) ]. (bula de Tetrabenazina, Interações medicamentosas)

  • TioridazinaantipsicóticoGrave

    CONTRAINDICATIONS Thioridazine hydrochloride tablet use should be avoided in combination with other drugs that are known to prolong the QTc interval and in patients with congenital long QT syndrome or a history of cardiac arrhythmias. (bula de Tioridazina, Contraindicações)

  • TramadolopioideGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Tranilciprominainibidor da MAOGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • TrazodonaantidepressivoGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Trimipraminaantidepressivo tricíclicoGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • VenlafaxinaIRSNGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (bula de Vepdegestranto, Advertências e precauções)

  • VilazodonaISRSGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • VortioxetinaantidepressivoGrave

    Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

  • ZiprasidonaantipsicóticoGrave

    …drugs, ziprasidone is contraindicated: • in patients with a known history of QT prolongation (including congenital long QT syndrome) • in patients with recent acute myocardial infarction • in patients with uncompensated heart failure Pharmacokinetic/pharmacodynamic studies between ziprasidone and other drugs that prolong the QT interval have not been performed. (bula de Ziprasidona, Contraindicações)

  • ZolmitriptanatriptanoGrave

    S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

Interações moderadas (62)

  • Aprepitantoinibidor da CYP3A4Moderada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • Arformoterolagonista beta-adrenérgicoModerada

    MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (bula de Arformoterol, Interações medicamentosas)

  • Armodafinilaestimulante do SNCModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • Bosentanaindutor da CYP3A4Moderada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • CarbamazepinaanticonvulsivanteModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • CenobamatoanticonvulsivanteModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • Cinacalceteinibidor da CYP2D6Moderada

    QT Interval Prolongation and V entricular A rr h ythmia Decreases in serum calcium can also prolong the QT interval, potentially resulting in ventricular arrhythmia. (bula de Cinacalcete, Advertências e precauções)

  • ClobazambenzodiazepínicoModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • Deferasiroxsuplemento de ferroModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • Desfluranoanestésico geralModerada

    Carefully monitor cardiac rhythm when administering SUPRANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (bula de Desflurano, Advertências e precauções)

  • DexametasonacorticosteroideModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • Droperidolantagonista da dopaminaModerada

    …cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS, Drug Interactions ), and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs… (bula de Droperidol, Advertências)

  • EfavirenzantirretroviralModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • Efavirenz + lamivudina + tenofovirantirretroviralModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • EribulinaModerada

    QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (bula de Eribulina, Advertências e precauções)

  • EslicarbazepinaanticonvulsivanteModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • EtravirinaantirretroviralModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • FenitoínaanticonvulsivanteModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • Fentermina + topiramatoestimulante do SNCModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • Formoterolagonista beta-adrenérgicoModerada

    …Antidepressants, QTc Prolonging Drugs Formoterol, as with other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (bula de Formoterol, Interações medicamentosas)

  • FosfenitoínaanticonvulsivanteModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • GosserrelinaModerada

    Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (bula de Gosserrelina, Advertências e precauções)

  • GriseofulvinaantifúngicoModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • Isofluranoanestésico geralModerada

    Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (bula de Isoflurano, Advertências e precauções)

  • Lapatinibeinibidor da glicoproteína PModerada

    TYKERB may prolong the QT interval in some patients. (bula de Lapatinibe, Advertências e precauções)

  • Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (bula de Leuprorrelina, Advertências e precauções)

  • Lofexidinaagonista alfa-adrenérgicoModerada

    Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (bula de Lofexidina, Advertências e precauções)

  • Lorlatinibeindutor da CYP3A4Moderada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • MefloquinaantimaláricoModerada

    Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (bula de Mefloquina, Interações medicamentosas)

  • MetotrexatoimunossupressorModerada

    In a crossover trial in 76 pediatric patients, intravenous ondansetron did not increase blood levels of high-dose methotrexate. (bula de Ondansetrona, Interações medicamentosas)

  • MetronidazolantibióticoModerada

    Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (bula de Metronidazol, Interações medicamentosas)

  • Mifepristonainibidor da CYP3A4Moderada

    There is little or no experience with high exposure, concomitant dosing with other QT-prolonging drugs, or potassium channel variants resulting in a long QT interval. [See Warnings & Precautions ( 5.6 )] To minimize risk, the lowest effective dose should always be used. (bula de Mifepristona, Advertências e precauções)

  • Mitapivateindutor da CYP3A4Moderada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • Mitotanoindutor da CYP3A4Moderada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • Modafinilaestimulante do SNCModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • MoxifloxacinofluoroquinolonaModerada

    Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (bula de Moxifloxacino, Advertências e precauções)

  • Nafcilinaantibiótico da classe das penicilinasModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • NalbufinaopioideModerada

    Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (bula de Nalbufina, Interações medicamentosas)

  • NevirapinaantirretroviralModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • OxcarbazepinaanticonvulsivanteModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • PaliperidonaantipsicóticoModerada

    …combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval. (bula de Paliperidona, Advertências e precauções)

  • PasireotidaModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • PonesimodeimunossupressorModerada

    Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (bula de Ponesimode, Interações medicamentosas)

  • PrimaquinaantimaláricoModerada

    QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (bula de Primaquina, Interações medicamentosas)

  • PrimidonaanticonvulsivanteModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • QuetiapinaantipsicóticoModerada

    …Class 1A antiarrythmics (e.g., quinidine, procainamide) or Class III antiarrythmics (e.g., amiodarone, sotalol), antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval (e.g., pentamidine, levomethadyl acetate, methadone). (bula de Quetiapina, Advertências e precauções)

  • RifabutinaantibióticoModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • RifampicinaantibióticoModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • RifapentinaantibióticoModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • RilpivirinaantirretroviralModerada

    In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (bula de Rilpivirina, Advertências e precauções)

  • RitonavirantirretroviralModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • Rocurôniobloqueador neuromuscularModerada

    QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (bula de Rocurônio, Advertências e precauções)

  • Sevofluranoanestésico geralModerada

    Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (bula de Sevoflurano, Advertências)

  • SorafenibeModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)

  • SotalolbetabloqueadorModerada

    Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (bula de Sotalol, Interações medicamentosas)

  • Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (bula de Subcitrato de bismuto + metronidazol + tetraciclina, Advertências e precauções)

  • SunitinibeModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)

  • Suzetriginaindutor da CYP3A4Moderada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • TopiramatoanticonvulsivanteModerada

    Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

  • Toremifenomodulador seletivo do receptor de estrogênioModerada

    …procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron). (bula de Toremifeno, Interações medicamentosas)

  • Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (bula de Triptorrelina, Advertências e precauções)

  • Umeclidínio + vilanterolanticolinérgicoModerada

    …like other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval or within 2 weeks of discontinuation of such agents, because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (bula de Umeclidínio + vilanterol, Interações medicamentosas)

Menções leves (25)

  • Anagrelidamedicamento que prolonga o intervalo QTLeve

    CYP1A2 substrates: AGRYLIN demonstrates limited inhibitory activity towards CYP1A2 in vitro and may alter the exposure of concomitant CYP1A2 substrates (e.g., theophylline, fluvoxamine, ondansetron). (bula de Anagrelida, Interações medicamentosas)

  • Articaína + epinefrinaanestésico localLeve

    Interactions with general or local anesthetics have not been studied. (bula de Ondansetrona, Interações medicamentosas)

  • Atomoxetinainibidor da recaptação de noradrenalinaLeve

    Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). (bula de Ondansetrona, Advertências e precauções)

  • Bupivacaínaanestésico localLeve

    Interactions with general or local anesthetics have not been studied. (bula de Ondansetrona, Interações medicamentosas)

  • Bupivacaína + epinefrinaanestésico localLeve

    Interactions with general or local anesthetics have not been studied. (bula de Ondansetrona, Interações medicamentosas)

  • Chemotherapy In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron. (bula de Ondansetrona, Interações medicamentosas)

  • Cetaminadepressor do SNCLeve

    Interactions with general or local anesthetics have not been studied. (bula de Ondansetrona, Interações medicamentosas)

  • Chemotherapy In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron. (bula de Ondansetrona, Interações medicamentosas)

  • Cloroprocaínaanestésico localLeve

    Interactions with general or local anesthetics have not been studied. (bula de Ondansetrona, Interações medicamentosas)

  • Cocaínaanestésico localLeve

    Interactions with general or local anesthetics have not been studied. (bula de Ondansetrona, Interações medicamentosas)

  • Etomidatoanestésico geralLeve

    Interactions with general or local anesthetics have not been studied. (bula de Ondansetrona, Interações medicamentosas)

  • Chemotherapy In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron. (bula de Ondansetrona, Interações medicamentosas)

  • Fenterminaestimulante do SNCLeve

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (bula de Fentermina, Advertências e precauções)

  • Hidroxizinaanti-histamínicoLeve

    …(e.g., amiodarone, sotalol) antiarrhythmics, certain antipsychotics (e.g., ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (e.g., citalopram, fluoxetine), certain antibiotics (e.g., azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin); and others (e.g., pentamidine, methadone, ondansetron, droperidol). (bula de Hidroxizina, Precauções)

  • IsoniazidaantibióticoLeve

    Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). (bula de Ondansetrona, Advertências e precauções)

  • Lidocaínaanestésico localLeve

    Interactions with general or local anesthetics have not been studied. (bula de Ondansetrona, Interações medicamentosas)

  • Lidocaína + epinefrinaanestésico localLeve

    Interactions with general or local anesthetics have not been studied. (bula de Ondansetrona, Interações medicamentosas)

  • Lidocaína + prilocaínaanestésico localLeve

    Interactions with general or local anesthetics have not been studied. (bula de Ondansetrona, Interações medicamentosas)

  • Mepivacaínaanestésico localLeve

    Interactions with general or local anesthetics have not been studied. (bula de Ondansetrona, Interações medicamentosas)

  • MetoexitalbarbitúricoLeve

    Interactions with general or local anesthetics have not been studied. (bula de Ondansetrona, Interações medicamentosas)

  • Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome [see Adverse Reaction ( 6.2)]. (bula de Oxicodona + paracetamol, Interações medicamentosas)

  • Prilocaína + epinefrinaanestésico localLeve

    Interactions with general or local anesthetics have not been studied. (bula de Ondansetrona, Interações medicamentosas)

  • Propofoldepressor do SNCLeve

    Interactions with general or local anesthetics have not been studied. (bula de Ondansetrona, Interações medicamentosas)

  • Ropivacaínaanestésico localLeve

    Interactions with general or local anesthetics have not been studied. (bula de Ondansetrona, Interações medicamentosas)

  • Viloxazinainibidor da recaptação de noradrenalinaLeve

    Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). (bula de Ondansetrona, Advertências e precauções)

Nenhuma interação significativa relatada (3)

  • Atracúriobloqueador neuromuscularSem interação

    Alfentanil and Atracurium Ondansetron does not alter the respiratory depressant effects produced by alfentanil or the degree of neuromuscular blockade produced by atracurium. (bula de Ondansetrona, Interações medicamentosas)

  • Fosaprepitantoinibidor da CYP3A4Sem interação

    Intervention No dosage adjustment needed Examples ondansetron, granisetron, dolasetron 7.2 Effect of Other Drugs on the Pharmacokinetics of Fosaprepitant/Aprepitant Aprepitant is a CYP3A4 substrate [see Clinical Pharmacology (12.3)] . (bula de Fosaprepitanto, Interações medicamentosas)

  • TemazepambenzodiazepínicoSem interação

    Temazepam The coadministration of ondansetron had no effect on the pharmacokinetics and pharmacodynamics of temazepam. (bula de Ondansetrona, Interações medicamentosas)

Verifique Ondansetrona com tudo o que você toma. Adicione sua lista completa; todos os pares são verificados de uma vez.

Abrir no verificador

Não é aconselhamento médico. A gravidade reflete a redação da bula, não as suas circunstâncias. Um alerta “grave” pode ser rotina sob supervisão, e um “leve” pode ser importante em doses altas. Pergunte a um farmacêutico.